0000876661-12-000613.txt : 20121002
0000876661-12-000613.hdr.sgml : 20121002
20121002165546
ACCESSION NUMBER: 0000876661-12-000613
CONFORMED SUBMISSION TYPE: 25-NSE
PUBLIC DOCUMENT COUNT: 2
FILED AS OF DATE: 20121002
DATE AS OF CHANGE: 20121002
EFFECTIVENESS DATE: 20121002
SUBJECT COMPANY:
COMPANY DATA:
COMPANY CONFORMED NAME: PAR PHARMACEUTICAL COMPANIES, INC.
CENTRAL INDEX KEY: 0000878088
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 223122182
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 25-NSE
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-10827
FILM NUMBER: 121124266
BUSINESS ADDRESS:
STREET 1: 300 TICE BOULEVARD
CITY: WOODCLIFF LAKE
STATE: NJ
ZIP: 07677
BUSINESS PHONE: 201-802-4000
MAIL ADDRESS:
STREET 1: 300 TICE BOULEVARD
CITY: WOODCLIFF LAKE
STATE: NJ
ZIP: 07677
FORMER COMPANY:
FORMER CONFORMED NAME: PHARMACEUTICAL RESOURCES INC
DATE OF NAME CHANGE: 19940526
FILED BY:
COMPANY DATA:
COMPANY CONFORMED NAME: NEW YORK STOCK EXCHANGE LLC
CENTRAL INDEX KEY: 0000876661
IRS NUMBER: 000000000
STATE OF INCORPORATION: NY
FILING VALUES:
FORM TYPE: 25-NSE
BUSINESS ADDRESS:
STREET 1: 11 WALL STREET
CITY: NEW YORK
STATE: NY
ZIP: 10005
BUSINESS PHONE: 212-656-2060
MAIL ADDRESS:
STREET 1: 11 WALL STREET
CITY: NEW YORK
STATE: NY
ZIP: 10005
FORMER COMPANY:
FORMER CONFORMED NAME: NEW YORK STOCK EXCHANGE INC
DATE OF NAME CHANGE: 19910628
25-NSE
1
primary_doc.xml
X0203
0000876661
NEW YORK STOCK EXCHANGE LLC
878088
PAR PHARMACEUTICAL COMPANIES, INC.
001-10827
300 Tice Boulevard
Woodcliff Lake
NJ
NEW JERSEY
07677
(201) 802-4000
Common Stock
17 CFR 240.12d2-2(a)(3)
Paras Madho
Director
2012-10-02
EX-99.25
2
ruleprovisionnotice.htm
NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES
The New York Stock Exchange hereby notifies the SEC of its intention to remove the entire class of the stated securities from listing and registration on the Exchange at the opening of business on October 15, 2012, pursuant to the provisions of Rule 12d2-2 (a).
[ X ] 17 CFR 240.12d2-2(a)(3) That on September 28, 2012 the instruments representing the securities comprising the entire class of this security came to evidence, by operation of law or otherwise, other securities in substitution therefore and represent no other right except, if such be the fact, the right to receive an immediate cash payment.
The merger between Par Pharmaceutical Companies, Inc. and Sky Growth Acquisition Corporation a wholly owned subsidiary of Sky Growth Holdings Corporation which is beneficially owned by an affiliate of TPG Capital, L.P. became effective on September 28, 2012, each share of Common Stock of Par Pharmaceutical Companies, Inc. was converted into $50.00 in cash per share.
The Exchange also notifies the Securities and Exchange Commission that as a result of the above indicated conditions this security was suspended from trading on October 1, 2012.